163 related articles for article (PubMed ID: 10385501)
1. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension.
Langleben D; Barst RJ; Badesch D; Groves BM; Tapson VF; Murali S; Bourge RC; Ettinger N; Shalit E; Clayton LM; Jöbsis MM; Blackburn SD; Crow JW; Stewart DJ; Long W
Circulation; 1999 Jun; 99(25):3266-71. PubMed ID: 10385501
[TBL] [Abstract][Full Text] [Related]
2. Endothelin-1 across the lung circulation in patients with pulmonary arterial hypertension and influence of epoprostenol infusion.
Selimovic N; Andersson B; Bergh CH; Sakiniene E; Carlsten H; Rundqvist B
J Heart Lung Transplant; 2009 Aug; 28(8):808-14. PubMed ID: 19632577
[TBL] [Abstract][Full Text] [Related]
3. Continuous intravenous administration of a low dose of epoprostenol greatly decreased serum concentrations of endothelin-1 in primary pulmonary hypertension--a case report.
Kakinuma Y; Honma S; Morimoto T; Maruyama H; Yamazaki A; Ishimitsu T; Yamaguchi I
Angiology; 2005; 56(5):641-5. PubMed ID: 16193207
[TBL] [Abstract][Full Text] [Related]
4. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
Badesch DB; Tapson VF; McGoon MD; Brundage BH; Rubin LJ; Wigley FM; Rich S; Barst RJ; Barrett PS; Kral KM; Jöbsis MM; Loyd JE; Murali S; Frost A; Girgis R; Bourge RC; Ralph DD; Elliott CG; Hill NS; Langleben D; Schilz RJ; McLaughlin VV; Robbins IM; Groves BM; Shapiro S; Medsger TA
Ann Intern Med; 2000 Mar; 132(6):425-34. PubMed ID: 10733441
[TBL] [Abstract][Full Text] [Related]
5. [Effects of long-term treatment with prostacyclin on plasma adrenomedullin in patients with primary pulmonary hypertension].
Nakayama T; Ishikita T; Matsuura H; Saji T
J Cardiol; 2001 Nov; 38(5):263-71. PubMed ID: 11729726
[TBL] [Abstract][Full Text] [Related]
6. [Ten years' experience in continuous intravenous epoprostenol therapy in severe pulmonary arterial hypertension].
Pombo Jiménez M; Escribano Subías P; Tello de Meneses R; Gómez-Sánchez MA; Delgado Jiménez J; Dalmau González-Gallarza R; Lázaro Salvador M; Hernández Rodríguez I; Tascón Pérez J; Sáenz de la Calzada C
Rev Esp Cardiol; 2003 Mar; 56(3):230-5. PubMed ID: 12622952
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children.
Nakayama T; Shimada H; Takatsuki S; Hoshida H; Ishikita T; Matsuura H; Saji T
Circ J; 2007 Nov; 71(11):1785-90. PubMed ID: 17965503
[TBL] [Abstract][Full Text] [Related]
8. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
Barst RJ; Rubin LJ; Long WA; McGoon MD; Rich S; Badesch DB; Groves BM; Tapson VF; Bourge RC; Brundage BH; Koerner SK; Langleben D; Keller CA; Murali S; Uretsky BF; Clayton LM; Jöbsis MM; Blackburn SD; Shortino D; Crow JW;
N Engl J Med; 1996 Feb; 334(5):296-301. PubMed ID: 8532025
[TBL] [Abstract][Full Text] [Related]
9. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
McLaughlin VV; Genthner DE; Panella MM; Rich S
N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
[TBL] [Abstract][Full Text] [Related]
10. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.
Sitbon O; Humbert M; Nunes H; Parent F; Garcia G; Hervé P; Rainisio M; Simonneau G
J Am Coll Cardiol; 2002 Aug; 40(4):780-8. PubMed ID: 12204511
[TBL] [Abstract][Full Text] [Related]
11. Prostacyclin for pulmonary hypertension.
Paramothayan NS; Lasserson TJ; Wells AU; Walters EH
Cochrane Database Syst Rev; 2002; (3):CD002994. PubMed ID: 12137667
[TBL] [Abstract][Full Text] [Related]
12. Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol.
Demerouti E; Karyofyllis P; Manginas A; Anthi A; Karatasakis G; Athanassopoulos G; Voudris V
Am J Cardiovasc Drugs; 2019 Apr; 19(2):99-105. PubMed ID: 30671881
[TBL] [Abstract][Full Text] [Related]
13. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.
Rubin LJ; Mendoza J; Hood M; McGoon M; Barst R; Williams WB; Diehl JH; Crow J; Long W
Ann Intern Med; 1990 Apr; 112(7):485-91. PubMed ID: 2107780
[TBL] [Abstract][Full Text] [Related]
14. Intrapulmonary shunting in primary pulmonary hypertension: an observation in two patients treated with epoprostenol sodium.
Castro PF; Bourge RC; McGiffin DC; Benza RL; Fan P; Pinkard NB; McGoon MD
Chest; 1998 Jul; 114(1):334-6. PubMed ID: 9674493
[TBL] [Abstract][Full Text] [Related]
15. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group.
Hinderliter AL; Willis PW; Barst RJ; Rich S; Rubin LJ; Badesch DB; Groves BM; McGoon MD; Tapson VF; Bourge RC; Brundage BH; Koerner SK; Langleben D; Keller CA; Murali S; Uretsky BF; Koch G; Li S; Clayton LM; Jöbsis MM; Blackburn SD; Crow JW; Long WA
Circulation; 1997 Mar; 95(6):1479-86. PubMed ID: 9118516
[TBL] [Abstract][Full Text] [Related]
16. Moderate-term effect of epoprostenol on severe portopulmonary hypertension.
Kato H; Katori T; Nakamura Y; Kawarasaki H
Pediatr Cardiol; 2003; 24(1):50-3. PubMed ID: 12574979
[TBL] [Abstract][Full Text] [Related]
17. Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.
Hall SM; Davie N; Klein N; Haworth SG
Eur Respir J; 2011 Oct; 38(4):851-60. PubMed ID: 21406517
[TBL] [Abstract][Full Text] [Related]
18. Effects of continuous intravenous epoprostenol therapy on advanced primary pulmonary hypertension in Taiwanese patients.
Hsu HH; Chen JS; Kuo SH; Chiang FT; Ko WJ; Kuo SW; Huang SC; Lee YC
J Formos Med Assoc; 2005 Jan; 104(1):60-3. PubMed ID: 15660181
[TBL] [Abstract][Full Text] [Related]
19. High plasma serotonin levels in primary pulmonary hypertension. Effect of long-term epoprostenol (prostacyclin) therapy.
Kéreveur A; Callebert J; Humbert M; Hervé P; Simonneau G; Launay JM; Drouet L
Arterioscler Thromb Vasc Biol; 2000 Oct; 20(10):2233-9. PubMed ID: 11031209
[TBL] [Abstract][Full Text] [Related]
20. Treprostinil for pulmonary hypertension.
Vachiéry JL; Naeije R
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
